Goldman Sachs’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Goldman Sachs’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-57,337	Closed	-$75K	–	6032
2018 Q3	$75K	Sell	57,337 -5,534	-9%	-$8.59K	﹤0.01%	5215
2018 Q2	$85K	Buy	+62,871	New	+$96.3K	﹤0.01%	5253
2018 Q1	–	Sell	-11,934	Closed	-$27K	–	6726
2017 Q4	$27K	Sell	11,934 -478	-4%	-$1.21K	﹤0.01%	6074
2017 Q3	$42K	Buy	+12,412	New	+$41.8K	﹤0.01%	6296
2017 Q2	–	Sell	-10,581	Closed	-$36K	–	7213
2017 Q1	$36K	Buy	+10,581	New	+$41.1K	﹤0.01%	6377
2016 Q4	–	Sell	-49,525	Closed	-$210K	–	7338
2016 Q3	$210K	Buy	49,525 +9,550	+24%	+$30.9K	﹤0.01%	5793
2016 Q2	$96K	Buy	+39,975	New	+$145K	﹤0.01%	6152
2015 Q4	–	Sell	-27,781	Closed	-$108K	–	7692
2015 Q3	$108K	Buy	+27,781	New	+$128K	﹤0.01%	6437
2015 Q2	–	Sell	-46,283	Closed	-$312K	–	7707
2015 Q1	$312K	Buy	46,283 +10,445	+29%	+$51.7K	﹤0.01%	5605
2014 Q4	$116K	Buy	+35,838	New	+$144K	﹤0.01%	6518

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs's AST Position: Q4 2018 in Review

Goldman Sachs sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 57,337 shares — an estimated $75K sold.

Goldman Sachs first reported a position in AST in Q4 2014 and held it in 10 quarters. The position peaked at $312K in Q1 2015. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

Goldman Sachs reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
Goldman Sachs sold 57,337 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $75K.
Goldman Sachs first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 10 quarters.
Goldman Sachs's Asterias Biotherapeutics Inc. Series A position peaked at $312K in Q1 2015.
46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.